T h e ne w e ngl a nd jou r na l o f m e dicine M ultiple sclerosis and systemic lupus erythematosus (SLE) are autoimmune diseases caused by largely unknown environmental factors acting in genetically susceptible persons. Genomewide association studies have provided statistical support for more than 110 independent signals for multiple sclerosis and 43 for SLE. [1] [2] [3] Although several signals are near genes involved in immunologic processes, the effector mechanisms for most associations remain unknown.
A useful approach to explore disease mechanisms is to search for genetic variants that affect both the risk of autoimmune disease and quantitative immune variables such as circulating levels of immune-cell populations, immunoglobulins, and cytokines. 4, 5 This approach can reveal diseaserelated endophenotypes and is especially informative when variables are measured in healthy persons, avoiding secondary effects of the disease and its therapy. 4 For such studies, the genetic structure of the Sardinian population, 6 with prevalences of multiple sclerosis and SLE that are among the highest in the world, 7, 8 is likely to facilitate the detection of relevant variants missed in studies of cosmopolitan populations. 6, 9, 10 A genomewide association scan for risk of multiple sclerosis was carried out in Sardinia, Italy. We implemented a strategy to follow up association signals in other populations and assess mechanisms through the characterization of potentially correlated quantitative immune variables and transcript and expression studies. We focused on an association signal in TNFSF13B, which encodes tumor necrosis factor superfamily member 13b (also known as B-cell activating factor [BAFF] ). BAFF is a cytokine and drug target that is primarily produced by monocytes and neutrophils and that is essential for B-cell activation, differentiation, and survival. 11, 12 Me thods
Study Sample Sets
Coincident associations were assessed in casecontrol sets of 2934 patients with multiple sclerosis, 411 patients with SLE, and 3392 controls from across Sardinia, as well as in a population cohort (SardiNIA study) of 6921 volunteers from the Lanusei valley in Sardinia. 6, 13 Tests of replication involved the use of case-control sets from mainland Italy (2292 patients with multiple sclerosis, 503 patients with SLE, and 2563 controls), Sweden (4548 patients with multiple sclerosis and 3481 controls), the United Kingdom (3176 patients with multiple sclerosis and 2958 controls), and the Iberian Peninsula (1120 patients with SLE and 1300 controls). All participants provided written informed consent.
Genotyping, Imputation, and Variant Characterization
A subgroup of 2273 patients with multiple sclerosis and 2148 controls from Sardinia were genotyped with the Affymetrix SNP Array 6.0 (574,519 single-nucleotide polymorphisms [SNPs] ), and 6602 SardiNIA volunteers were genotyped with four Illumina arrays (OmniExpress, ImmunoChip, Cardio-MetaboChip, and ExomeChip; 890,542 SNPs in total). 6, 14 A much denser genetic map (up to 13.6 million SNPs) was constructed from a reference panel of 2120 Sardinians who underwent whole-genome sequencing and was then propagated ("imputed") to all genotyped persons. 6 Furthermore, at the TNFSF13B locus, we constructed a more refined map, which also included insertion-deletion variants (indels) called by use of the Genome Analysis Tool Kit (GATK) HaplotypeCaller tool. This locus-specific map was used as a reference panel for TNFSF13B locus imputation in the case-control and SardiNIA cohorts. Custom TaqMan assays were designed to genotype variants of interest (rs12874404 and an insertion-deletion variant, GCTGT→A, that we refer to as BAFF-var) in appropriate Sardinian and non-Sardinian samples.
Association Analyses
Genomewide association studies in Sardinian multiple sclerosis case-control sets and locusspecific association studies in the SardiNIA cohort were performed as described previously. 6, 14 Single-variant follow-up association analyses focusing on rs12874404 and BAFF-var (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org) used PLINK software, version 1.9 (https:/ / www . cog-genomics . org/ plink2). P values and effect sizes for SLE were calculated with the use of METAL software (http://genome . sph . umich . edu/ wiki/ METAL_ Program). Bonferroni correction for multiple testing was applied to the nominal P value (P = 0.05). Conditional analyses for risk of multiple sclerosis and for quantitative traits were performed by adding either BAFF-var or rs12874404 as a covariate to the basic model.
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Immunologic Phenotyping and Serum Quantifications in the SardiNIA Cohort
Broad leukocyte types, including lymphocytes, neutrophils, and monocytes, were quantified with the use of an automated counter in up to 5937 genotyped volunteers. Flow cytometry was used to profile immune-cell subpopulations in 3669 volunteers, as described previously in a study involving a smaller sample. 4 In addition, B-cell and monocyte subsets were assessed cytometrically in 1902 persons (Table S2 in To determine whether the effect of BAFF-var on levels of soluble BAFF was fully accounted for by effects on transcription, we performed a conditional linear regression analysis of data on 522 persons for whom both soluble BAFF protein levels and RNA sequencing data were available. The effect of BAFF-var on soluble BAFF levels, with and without TNFSF13B 3′ UTR transcript levels, was assessed with a likelihood-ratio test.
MicroRNA Effects on BAFF Expression
Expression studies were performed with primary monocytes and HeLa, HEK293T, and THP1 cells. Primary monocytes were isolated from peripheralblood mononuclear cells by negative selection. RNA extraction, complementary DNA preparation, and quantitative polymerase-chain-reaction (PCR) analyses were performed with the use of the primers listed in 
Differentiation and Positive Selection Analyses
To assess positive selection, we used standard statistical tests to evaluate allele-frequency differentiation (fixation index 15 and population branch statistic 16 ) and haplotype diversity (integrated haplotype score 17 and the number of segregating sites by length 18 ) in sequences from 1081 unrelated Sardinians as compared with sequences from European participants in phase 3 of the 1000 Genomes Project. 19 For any given statistic, we calculated a "genomic percentile," ranking BAFF-var relative to 3042 other variants that were sampled across the genome and matched for minor-allele frequency in Sardinians, local recombination rates, and levels of background selection.
R esult s
Association of a Variant in TNFSF13B with Multiple Sclerosis
Extending previous work 14 with more samples and an improved genetic map, we conducted a sequencing-based genomewide association study involving 2273 Sardinian patients with multiple sclerosis and 2148 controls, analyzing approximately 12.2 million SNPs. 6 The SNPs that showed a suggestive association (P<5×10 −6 ) ( Table S5 in the Supplementary Appendix) included variant rs12874404 near TNFSF13B. This variant is in moderate linkage disequilibrium (r 2 = 0.44) with SNP rs9520836, which we previously found to be associated with increased numbers of B cells. 4 This locus was thus a strong candidate for evaluating coincident associations between disease risk and endophenotypes and was further investigated.
We confirmed the association with multiple
T h e ne w e ngl a nd jou r na l o f m e dicine sclerosis at this locus by directly genotyping rs12874404 in a sample of Sardinians that included the discovery set and some additional Sardinians (totaling 2934 patients and 3392 controls) and observing a genomewide significant association (odds ratio, 1.27; P = 1.52×10 −9 ). (See the Results section in the Supplementary Appendix.) However, we found no association between rs12874404 and multiple sclerosis in the casecontrol sets from mainland Italy, the United Kingdom, or Sweden (the lowest P value was found in the Italian sample [P = 0.51]), even though the risk allele was common and sample sizes provided high statistical power. (See the Results section in the Supplementary Appendix.) Thus, rs12874404 is unlikely to be the variant driving the association.
Because the pattern of linkage disequilibrium around rs12874404 differs between Sardinia and mainland Europe (Fig. S1A in the Supplementary Appendix), we considered whether the signal might come from a variant, such as an indel, that was not assessed in our initial genomewide association study and that was in stronger linkage disequilibrium with rs12874404 in Sardinia than elsewhere. Searching for such variants, we found an indel with GCTGT replaced by A, which had an r 2 of 0.76 with rs12874404 in Sardinia but an r 2 of only 0.44 among European participants in the 1000 Genomes Project (Fig. S1B in the Supplementary Appendix). Directly genotyping the indel in our Sardinian cohort showed the minor allele (A), which we named "BAFF-var," as the variant most strongly associated with multiple sclerosis (odds ratio, 1.27; P = 1.23×10 −9 ) (Fig. 1A) . Conditional analyses showed BAFF-var or rs12874404 completely explaining the association at TNFSF13B, excluding secondary signals among the approximately 10,000 variants assessed at the locus. (See the Results section in the Supplementary Appendix.)
We further fine-mapped the association through cross-population comparisons. BAFF-var is especially common across Sardinia (frequency, 26.5%) and progressively less common in southern Europe (5.7% in Italy and 4.9% in Spain) and northern Europe (1.8% in the United Kingdom and Sweden). We estimated that we would have power to detect an association with BAFF-var only in the available Italian samples. (See the Results section in the Supplementary Appendix.) By genotyping these samples (in which we initially did not replicate the rs12874404 association), we replicated the association of BAFF-var with risk of multiple sclerosis (odds ratio, 1.25; P = 0.01) ( Table S6 in the Supplementary Appendix). Together, these findings pinpoint BAFF-var as the variant in TNFSF13B that is most strongly associated with multiple sclerosis.
BAFF-var as a General Autoimmunity Variant
BAFF is also a prime candidate for involvement in other autoimmune diseases, especially SLE 20 ; belimumab, which targets BAFF, has been approved for the treatment of SLE by the Food and Drug Administration. 12 We found that BAFF-var was associated with SLE in the case-control sets from Sardinia (odds ratio, 1.38; P = 4.09×10 −5 ), mainland Italy (odds ratio, 1.49; P = 0.002), and the Iberian Peninsula (odds ratio, 1.55; P = 3.05×10 −4 ), with an odds ratio of 1.44 (P = 6.74×10 −10 ) in a combined analysis across all samples (Table S6 in the Supplementary Appendix). These findings indicate that the effect of BAFF-var is not restricted to multiple sclerosis alone.
Associations of BAFF-var with Immune Endophenotypes
We next asked whether BAFF-var might also account for the previously observed associations between variants at the TNFSF13B locus and elevated numbers of B lymphocytes. 4 Assessing a much denser set of markers (including indels) in an expanded sample of 3669 persons from the ) (Fig. 1C , and Table S9 in the Supplementary Appendix). It also increased levels of total IgG (P = 1.68×10 −12 ), IgG1 (P = 2.24×10 −14 ), IgA (P = 7.64×10 −9 ), and IgM (P = 4.70×10 −8 ) (Fig. S2 and Table S9 in the Supplementary Appendix). Finally, we found that BAFF-var was also the lead TNFSF13B variant (P = 9.07×10 −13 ) associated with reduced monocyte counts in SardiNIA volunteers (Fig. 1D , and Table S9 in the Supplementary Appendix), with the largest effect on "classical" CD14+CD16− monocytes (Table S10 in the Supplementary Appendix) .
Overall, BAFF-var was the top variant in genomewide significant associations (P<6.9×10 −9 ), 6 with 18 immune endophenotypes (Tables S7 through S10 in the Supplementary Appendix). For each of these traits, conditional analysis showed that BAFF-var explained the entire association at the locus (Table S11 in the Supplementary Appendix).
We also found that soluble BAFF levels were significantly higher in patients with multiple sclerosis or SLE than in controls. Furthermore, using preclinical samples available for SardiNIA volunteers in whom multiple sclerosis developed up to 12 years later, we observed elevated levels of soluble BAFF before disease diagnosis (Table  S12 and the Results section in the Supplementary Appendix). We infer that BAFF-var is the causal variant driving an increase in soluble BAFF and a cascade of immune effects leading to increased autoimmunity risk.
Effect of BAFF-var on Levels of Soluble BAFF
The observation that BAFF-var creates an alternative polyadenylation motif, AATAAA, from the sequence AAT[GCTGT/A]AA prompted the hypothesis that the variant 3′ UTR could raise soluble BAFF levels by generating a truncated TNFSF13B transcript in the 3′ UTR. Indeed, in 606 sequenced leukocyte transcriptomes of SardiNIA participants (Fig. 2) , BAFF-var correlated with a decrease of approximately 35% in the longer transcript per allele (P = 8.34×10 −86 ) (Fig. 1E, and  Fig. S3 in the Supplementary Appendix), an effect confirmed by quantitative PCR analysis of primary monocyte RNA (Fig. S4 in the Supplementary Appendix). Thus, BAFF-var generates a shorter TNFSF13B 3′ UTR.
The transcriptome data also implicated BAFFvar as an expression quantitative trait locus that increases TNFSF13B expression (P = 2.37×10 −13 ) (Fig. 1F) . However, the elevated mRNA levels could explain only 24 to 27% of the effect on protein (soluble BAFF) levels (Fig. 3A , and the Results section in the Supplementary Appendix), indicating that an increase in translation level was also probably involved. Higher levels of BAFF-var protein could be due to the presence of miRNA sites in the longer, but not in the shorter, 3′ UTR that might reduce protein production from the longer 3′ UTR. 21 We identified in silico candidate miRNA sites that were absent from the truncated 3′ UTR (Table S4 in the Supplementary Appendix) and tested them by pulling down miRNA-mRNA complexes from THP1 lysates using biotinylated RNA probes for the TNFSF13B wild-type 3′ UTR and the variant 3′ UTR (Fig. S5A in the Supplementary Appendix). The miRNAs in the miR-15/107 family 22 and miR-494 were more enriched in the probe for the wild-type 3′ UTR than in that for the variant 3′ UTR (Fig. S5B in the Supplementary Appendix), suggesting their preferential interaction with the longer 3′ UTR.
Confirming their inhibitory effect on BAFF expression, overexpression of miR-15a, miR-497, and miR-646, but not miR-16 and miR-494, significantly down-regulated levels of endogenous BAFF protein in THP1 cells (Fig. 3B and 3C) . One of these miRNAs, miR-15a, is highly expressed in primary monocytes (Fig. 3D) and thus was used in further validation experiments; its overexpression did not lower levels of endogenous TNFSF13B mRNA (Fig. 3E) , consistent with post-transcriptional regulation of BAFF protein production. Further supporting the regulation of BAFF protein levels, suppression of miR-15a with Overexpression of BAFF and Autoimmunity Risk the use of a locked nucleic acid-anti-miR increased production of soluble BAFF, both in THP1 cells and in primary monocytes ( Fig. 3F and 3G) .
To verify that miR-15a directly targets TNFSF13B, we cloned the wild-type BAFF 3′ UTR and the variant BAFF 3′ UTR into the pmirGLO reporter vector (Fig. 4A ) and analyzed luciferase activity in HeLa cells, which express low levels of miR-15a (Fig. S6 in the Supplementary Appendix). Cotransfection of miR-15a with pmirGLO wild-type BAFF 3′ UTR or pmirGLO variant BAFF 3′ UTR substantially reduced reporter levels, whereas reporters bearing mutated miR-15a binding sites were refractory to repression by miR-15a (Fig. 4B) .
Importantly, cotransfection of miR-15a with the variant BAFF 3′ UTR reduced reporter activity to levels similar to those seen for the wildtype BAFF 3′ UTR with one of the two miR-15a sites mutated, probably because one miR-15a site is absent from the variant BAFF 3′ UTR. These data indicate that BAFF-var raises soluble BAFF levels by favoring the production of a shorter transcript that is less inhibited by miR-15a. However, the higher luciferase activity from short reporters than from long reporters -either basal or cotransfected with miR-15a after mutating miR-15a binding sites -suggests that miR-15a does not fully explain the BAFF-var regulatory effects, and other miRNAs or RNAbinding proteins may also influence soluble BAFF levels.
Evidence of Positive Selection on BAFF-var
We next assessed whether the high frequency of BAFF-var in the isolated Sardinian population (Fig. S8A in the Supplementary Appendix) is consistent with the effects of random genetic drift acting across the genome or whether it is more likely the outcome of selection specifically favoring BAFF-var in Sardinia (positive selection). We found that BAFF-var has greater differences in frequency between Sardinians and Europeans than the vast majority of variants matched for allelic frequency in Sardinia and for other pertinent genetic features (99.97th genomic percentile for both fixation index and population branch statistic) (Table S13 and Fig. S8B in the Supplementary Appendix). In addition, the core haplotype carrying BAFF-var is remarkably longer than haplotypes carrying variants with matched genetic features (99.91th genomic percentile for integrated haplotype score and >99.99th genomic 
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T h e ne w e ngl a nd jou r na l o f m e dicine percentile for the number of segregating sites by length) (Figs. S8C and S9A in the Supplementary Appendix), a finding consistent with the hypothesis of positive selection for BAFF-var in Sardinia. The combination of extreme frequency differences and long core haplotype suggests that BAFF-var has been positively selected, 23 most likely as an adaptation to a selective pressure particularly prevalent in Sardinia.
Discussion
Since its discovery, BAFF has been studied in animal models, 24, 25 with an indication for a role in autoimmunity from mice that overexpress BAFF and have symptoms resembling those of human SLE and Sjögren's syndrome. 11 In contrast, case-control studies of human autoimmune disease that compared levels of soluble BAFF in biologic fluids have overall been inconclusive. (See the Discussion section in the Supplementary Appendix.) Furthermore, previous genomewide association studies provided no genetic evidence (in large consortium efforts 2, 26 ) or weak genetic evidence (in a small study 27 ) for its role in autoimmune disease. The convergent genetic, transcriptomic, and functional evidence now supports its effects in autoimmunity. A schematic depiction of the effects of BAFF-var is shown in Figure 5 . Our findings of naturally overexpressed BAFF in the general population are reminiscent of the large increases in IgM, IgG, and IgA in constitutive Baff-transgenic mice.
11 Furthermore, the lack of association of BAFF-var with any of the 153 T-cell traits that we assessed (Table S7 in the Supplementary Appendix) is consistent with the development of autoimmunity to the same extent in T-cell-sufficient and T-cell-deficient Baff-transgenic mice. 28 We infer that the increased risk of multiple sclerosis and SLE associated with BAFF overexpression mainly involves humoral immunity, consistent with the efficacy of B-cell-depleting therapies. 29, 30 However, the effects of BAFF-var are broad, and the involvement of specific B-cell and immunoglobulin subtypes in the pathogenesis of multiple sclerosis and SLE remains unclear and requires further explication. Moreover, how the observed BAFF-var-driven changes in peripheral blood relate to effects in mucosal and target organ compartments remains unresolved. For instance, the reduction in circulating monocytes reported here could result from their soluble BAFF-driven mobilization or transformation into macrophages or dendritic cells at sites of inflammation, consistent with findings in mice. 31 Alternatively, it may reflect negative feedback in response to the enhanced production of soluble BAFF in monocytes.
Nevertheless, besides supporting BAFF as a target in multiple sclerosis and SLE, our results have implications for clinical research. A pertinent one, to be assessed in further studies, 
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T h e ne w e ngl a nd jou r na l o f m e dicine would be that patients stratified according to BAFF-var status might show a differential benefit from anti-BAFF therapies. One might also anticipate that patients carrying BAFF-var would have a weaker response to B-cell-depleting therapies owing to a faster resurgence of memory B cells. 32 In fact, patients with SLE with higher basal levels of BAFF have been found to have poorer or shorter clinical responses to rituximab than those with lower levels. 33, 34 Our findings also underline the critical balance between regulation of immune responses to defend against infection and possible tissue damage from the elicited responses. Such evolutionary trade-offs might be a more general phenomenon, consistent with previous work. 4, 35 BAFF-var may have been positively selected in Sardinia by providing resistance to Plasmodium falciparum or P. vivax malaria, both of which were strikingly prevalent in Sardinia until their eradication in the 1950s. 36 The malaria-driven selective pressure to maintain high BAFF levels is supported by models of malaria in mice, in which BAFF overexpression confers protection against lethal malaria infection. 37 In addition, as shown here, BAFF-var increases antibody production, and classic findings showed that antibody transfer from adults with immunity to malaria to acutely infected children reduced blood-stage parasitemia and disease severity. 38 Overall, the evolutionary scenario we propose is that BAFF-var was selected as an adaptive response to malaria infection, resulting in an increased present-day risk of autoimmunity. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
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